Everolimus for hard-to-control focal epilepsy
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether the medicine everolimus (taken as a pill) can safely reduce seizures in adults with focal epilepsy that hasn't been controlled by other treatments. You would continue your current seizure medicines and add everolimus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have focal seizures (seizures that start in one part of the brain) that sometimes spread to both sides.
- Your seizures last at least 30 seconds and involve impaired awareness (not fully conscious).
- You have had at least 16 seizures in the past 8 weeks, with no seizure-free period longer than 21 days.
- You have tried at least two seizure medicines that didn't work, and your current medicines are stable for at least 12 weeks.
- You do not have other clearly treatable causes for your epilepsy, such as a recent stroke, brain tumor, or certain genetic conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
This trial tests if everolimus can improve social abilities in people with PTEN germline mutations who have social difficulties. It may help those with PTEN Hamartoma Tumor Syndrome by targeting a specific pathway in the body.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.